Allergan receives CEO Cancer Gold Standard accreditation Allergan.

Related StoriesOvarian cancers patients with a history of oral contraceptive make use of have better outcomesNew findings reveal association between colorectal cancer and melanoma drug treatmentFDA grants accelerated authorization for Tagrisso to treat individuals with advanced NSCLC As a company focused on serving various diverse individual populations with high unmet needs, Allergan is definitely honored to get the CEO Malignancy Gold Regular accreditation and invest in wellness applications that represent best practices for all companies to further improve the health and care of millions of people all over the world, stated Pyott.Logo – Cosmo Technologies Limited and Santarus, Inc. On February 17 filed suit against Actavis, 2015 in the U.S. District Courtroom for the District of Delaware seeking to prevent Actavis from commercializing its ANDA product prior to the expiration of certain U.S. Patents. The lawsuit was filed beneath the provisions of the Hatch-Waxman Act, resulting in a stay of final FDA approval of Actavis' ANDA for 30 months from the time the plaintiffs received notice of Actavis' ANDA filing or until last resolution of the matter before the courtroom, whichever occurs sooner, at the mercy of any other exclusivities. Based on available details, Actavis believes it might be a 1st applicant to document an ANDA for the generic version of Uceris® and, should its ANDA be approved, may be eligible for 180 days of generic market exclusivity.